The First International Symposium on Pheochromocytoma ... it is not currently cost effective to test every gene in every patient. Consideration of tumor location, presence of multiple tumors ...

In view of the array of symptoms, the patient was referred for medical evaluation of a suspected pheochromocytoma, a neuroendocrine tumor of the adrenal gland. He underwent 24-hour blood pressure ...

The role of chromogranin A in the assessment of surgical cure of pheochromocytoma was also investigated. The authors observed 21 consecutive patients who had pheochromocytomas at initial ...

scanning showed increased focal 131I activity that was consistent with right adrenal pheochromocytoma. The patient was advised to undergo surgical removal of the tumor but she refused, and surgery ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

Pheochromocytoma. Surgery ... Avoid abruptly discontinuing Toprol-XL in patients treated only for hypertension. When discontinuing chronically administered Toprol-XL especially in patients ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

“Pheochromocytoma and paraganglioma are rare tumors that form in and around the adrenal glands, and currently, there are no approved therapies available in the U.S. for patients with this rare disease ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.